Skip to content
Original Research
J Clin Psychiatry
May 2026
Aripiprazole Once-Monthly for Patients Diagnosed With Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed
Full Article
Read the complete peer-reviewed article in J Clin Psychiatry.
Clinical Summary
For patients with schizophrenia, the real-world question is not just whether a long-acting antipsychotic works, but how likely benefit is relative to harm. This analysis translates placebo-controlled trial results for aripiprazole once-monthly 400 mg into clinically useful metrics that quantify symptom response, relapse prevention, and adverse-event tradeoffs.
FAQ
What was the number needed to treat for aripiprazole once-monthly 400 mg in acute schizophrenia?
8 questions
Key Takeaways
In acute schizophrenia, the absolute response difference was substantial: 37.0% of patients receiving AOM 400 versus 14.4% receiving placebo achieved a ≥30% reduction in PANSS total score at week 10, yielding an NNT of 5 (95% CI, 4–8).
6 takeaways
Clinical Guide
How should clinicians use the article's benefit-risk data when considering aripiprazole once-monthly 400 mg for acute schizophrenia?
6 steps
Clinical Guide
How should clinicians use the article's benefit-risk data when considering continuation of aripiprazole once-monthly 400 mg for maintenance treatment of schizophrenia?
6 steps
Patient Guide
How can you prepare for a helpful conversation with your doctor about whether a once-monthly aripiprazole shot might be right for your schizophrenia care?
6 steps
